Nf1 haploinsufficiency and Icsbp deficiency synergize in the development of leukemias

Blood

Volumn 113, Issue 19, 2009, Pages 4690-4701

  Koenigsmann, Jessica ^a   Rudolph, Cornelia ^b   Sander, Sandrine ^c   Kershaw, Olivia ^d   Gruber, Achim D ^d   Bullinger, Lars ^c   Schlegelberger, Brigitte ^b   Carstanjen, Dirk ^a  

^a LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; MESSENGER RNA; INTERFERON REGULATORY FACTOR; NEUROFIBROMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE; GENE EXPRESSION; GENE LOSS; GENETIC TRANSCRIPTION; HEMATOPOIETIC TISSUE; HETEROZYGOSITY; LEUKEMIA; MALE; MORTALITY; MOUSE; MYELOPROLIFERATIVE DISORDER; NF1 GENE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; TUMOR SUPPRESSOR GENE; WILD TYPE; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CLONOGENIC ASSAY; DRUG POTENTIATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL; HETEROZYGOSITY LOSS; METABOLISM; MOUSE MUTANT; MYELOPOIESIS; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BONE MARROW CELLS; COLONY-FORMING UNITS ASSAY; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELLS; INTERFERON REGULATORY FACTORS; LEUKEMIA; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOPOIESIS; MYELOPROLIFERATIVE DISORDERS; NEUROFIBROMIN 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 66549130217     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-05-158485     Document Type: Article

References (45)

1. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med. 1994;330:597-601. (Pubitemid 24065793)
2. Side L, Taylor B, Cayouette M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med. 1997;336:1713-1720. (Pubitemid 27251785)
3. Yang G, Khalaf W, van de Locht L, et al. Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein. Mol Cell Biol. 2005;25:5869-5879. (Pubitemid 40946544)
4. Holtschke T, Lohler J, Kanno Y, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996;87:307-317. (Pubitemid 26359008)
5. Fehr T, Schoedon G, Odermatt B, et al. Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis. J Exp Med. 1997;185:921-931. (Pubitemid 27119876)
6. Giese NA, Gabriele L, Doherty TM, et al. Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression. J Exp Med. 1997;186:1535-1546. (Pubitemid 27479813)
7. Kantakamalakul W, Politis AD, Marecki S, et al. Regulation of IFN consensus sequence binding protein expression in murine macrophages. J Immunol. 1999;162:7417-7425. (Pubitemid 29277720)
8. Scharton-Kersten T, Contursi C, Masumi A, Sher A, Ozato K. Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection because of a primary defect in interleukin 12 p40 induction. J Exp Med. 1997;186:1523-1534. (Pubitemid 27479812)
9. Scheller M, Foerster J, Heyworth CM, et al. Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein. Blood. 1999;94:3764-3771.
10. Terszowski G, Waskow C, Conradt P, et al. Prospective isolation and global gene expression analysis of the erythrocyte colony-forming unit (CFU-E). Blood. 2005;105:1937-1945. (Pubitemid 40731775)
11. Hao SX, Ren R. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol. 2000;20:1149-1161. (Pubitemid 30069235)
12. Deng M, Daley GQ. Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. Blood. 2001;97:3491-3497.
13. Burchert A, Cai D, Hofbauer LC, et al. Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood. 2004;103:3480-3489. (Pubitemid 38525681)
14. Schmidt M, Nagel S, Proba J, et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood. 1998;91:22-29. (Pubitemid 28018725)
15. Schmidt M, Hochhaus A, Nitsche A, Hehlmann R, Neubauer A. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. Blood. 2001;97:3648-3650.
16. Schwieger M, Lohler J, Friel J, et al. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med. 2002;196:1227-1240. (Pubitemid 35304188)
17. Gurevich RM, Rosten PM, Schwieger M, Stocking C, Humphries RK. Retroviral integration site analysis identifies ICSBP as a collaborating tumor suppressor gene in NUP98-TOP1-induced leukemia. Exp Hematol. 2006;34:1192-1201. (Pubitemid 44291489)
18. Gebhard C, Schwarzfischer L, Pham TH, et al. Rapid and sensitive detection of CpG-methylation using methyl-binding (MB)-PCR. Nucleic Acids Res. 2006;34:e82.
19. Huang W, Saberwal G, Horvath E, et al. Leukemia-associated, constitutively active mutants of SHP2 protein tyrosine phosphatase inhibit NF1 transcriptional activation by the interferon consensus sequence binding protein. Mol Cell Biol. 2006;26:6311-6332. (Pubitemid 44277874)
20. Jacks T, Shih TS, Schmitt EM, et al. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet. 1994;7:353-361. (Pubitemid 24204410)
21. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet. 1996;12:137-143.
22. Cho BC, Shaughnessy JD Jr, Largaespada DA, et al. Frequent disruption of the Nf1 gene by a novel murine AIDS virus-related provirus in BXH-2 murine myeloid lymphomas. J Virol. 1995;69:7138-7146.
23. Largaespada DA, Shaughnessy JD Jr, Jenkins NA, Copeland NG. Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels. J Virol. 1995;69:5095-5102.
24. Turcotte K, Gauthier S, Tuite A, et al. A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice. J Exp Med. 2005;201:881-890. (Pubitemid 40524458)
25. Blaydes SM, Kogan SC, Truong BT, et al. Retroviral integration at the Epi1 locus cooperates with Nf1 gene loss in the progression to acute myeloid leukemia. J Virol. 2001;75:9427-9434.
26. Yin B, Delwel R, Valk PJ, et al. A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. Blood. 2009;113:1075-1085.
27. Huang W, Horvath E, Eklund EA. PU.1, interferon regulatory factor (IRF) 2, and the interferon consensus sequence-binding protein (ICSBP/IRF8) cooperate to activate NF1 transcription in differentiating myeloid cells. J Biol Chem. 2007;282:6629-6643.
28. Zhu C, Saberwal G, Lu Y, Platanias LC, Eklund EA. The interferon consensus sequence-binding protein activates transcription of the gene encoding neurofibromin 1. J Biol Chem. 2004;279:50874-50885. (Pubitemid 40017826)
29. National Center for Biotechnology Information. GEO: Gene Expression Omnibus. http://www.ncbi.nlm.nih.gov/geo. Accessed February 2009.
30. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12:144-148. (Pubitemid 26051293)
31. Kogan SC, Ward JM, Anver MR, et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 2002;100:238-245. (Pubitemid 35177453)
32. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12:144-148. (Pubitemid 26051293)
33. Le DT, Kong N, Zhu Y, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 2004;103:4243-4250. (Pubitemid 38685370)
34. Zhang YY, Vik TA, Ryder JW, et al. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med. 1998;187:1893-1902.
35. Ingram DA, Yang FC, Travers JB, et al. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med. 2000;191:181-188.
36. Zhang Y, Taylor BR, Shannon K, Clapp DW. Quantitative effects of Nf1 inactivation on in vivo hematopoiesis. J Clin Invest. 2001;108:709-715. (Pubitemid 32906199)
37. Ingram DA, Hiatt K, King AJ, et al. Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med. 2001;194:57-69. (Pubitemid 32660437)
38. Birnbaum RA, O'Marcaigh A, Wardak Z, et al. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell. 2000;5:189-195. (Pubitemid 30105448)
39. Kim A, Morgan K, Hasz DE, et al. Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice. Blood. 2007;109:1687-1691. (Pubitemid 46239603)
40. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17:277-282. (Pubitemid 36266902)
41. Mahgoub N, Taylor BR, Le Beau MM, et al. Myeloid malignancies induced by alkylating agents in Nf1 mice. Blood. 1999;93:3617-3623. (Pubitemid 29249806)
42. Chao RC, Pyzel U, Fridlyand J, et al. Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell. 2005;8:337-348. (Pubitemid 41443418)
43. Gutmann DH, Winkeler E, Kabbarah O, et al. Mlh1 deficiency accelerates myeloid leukemogenesis in neurofibromatosis 1 (Nf1) heterozygous mice. Oncogene. 2003;22:4581-4585. (Pubitemid 36920702)
44. Kondo M, Weissman IL, Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell. 1997;91:661-672. (Pubitemid 27513657)
45. Adolfsson J, Mansson R, Buza-Vidas N, et al. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell. 2005;121:295-306. (Pubitemid 40546396)